AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Apogee Therapeutics CMO Dambkowski Carl Sells 2725 Shares at $37.82-$38.55/Share.
ByAinvest
Friday, Sep 5, 2025 8:07 pm ET1min read
Apogee Therapeutics, Inc. [APGE] has announced that Chief Medical Officer Dambkowski Carl has engaged in two separate transactions involving the sale of shares. Firstly, Mr. Dambkowski Carl sold 2,535 shares at a price of $37.82 per share on September 3, 2025. Secondly, he sold an additional 190 shares at a price of $38.55 per share on the same date.
Apogee Therapeutics Inc. [APGE] has reported that its Chief Medical Officer, Carl Dambkowski, has engaged in two separate transactions involving the sale of shares. The first transaction saw Mr. Dambkowski sell 2,535 shares at a price of $37.82 per share on September 3, 2025. In a subsequent transaction on the same date, he sold an additional 190 shares at a price of $38.55 per share [1].These transactions come as Apogee Therapeutics continues to face financial challenges. The company reported a loss of $1.13 per share for the last quarter, falling short of analyst estimates. Analysts forecast an EPS of -3.09 for the current fiscal year [1].
Insiders own 42.77% of the company's stock, including Mr. Dambkowski, who now owns 236,273 shares after these transactions [1]. Despite the recent insider sales, institutional investors and hedge funds now hold 79.04% of the company's stock, reflecting a growing interest in the biotechnology sector [1].
Apogee Therapeutics is set to participate in the Stifel 2025 Virtual Immunology and Inflammation Forum, where members of management will engage in a fireside chat on September 16, 2025 [2]. The company is advancing novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications [2].
References:
[1] https://www.marketbeat.com/instant-alerts/filing-apogee-therapeutics-inc-apge-shares-bought-by-allostery-investments-lp-2025-09-03/
[2] https://www.biospace.com/press-releases/apogee-therapeutics-to-participate-at-the-stifel-2025-virtual-immunology-and-inflammation-forum
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet